Journal of International Oncology››2023,Vol. 50››Issue (12): 723-728.doi:10.3760/cma.j.cn371439-20230512-00136
• Original Articles •Previous ArticlesNext Articles
Li Shengping, Shi Yongzhu(), Ma Feng
Received:
2023-05-12Revised:
2023-06-19Online:
2023-12-08Published:
2024-01-16Contact:
Shi Yongzhu E-mail:115087111@qq.comLi Shengping, Shi Yongzhu, Ma Feng. Influencing factors analysis and prediction model construction of postoperative MIC comprehensive outcome in patients with early renal cell carcinoma treated with NSS[J]. Journal of International Oncology, 2023, 50(12): 723-728.
"
影响因素 | MIC组(n=66) | 非MIC组(n=108) | t/χ2值 | P值 |
---|---|---|---|---|
性别 | ||||
男 | 48 | 82 | 0.22 | 0.638 |
女 | 18 | 26 | ||
年龄(岁) | 59.65±10.61 | 57.91±10.25 | 1.06 | 0.289 |
体质量指数(kg/m2) | 23.98±2.89 | 25.26±2.96 | 2.81 | 0.006 |
病灶位置 | ||||
左肾 | 34 | 58 | 0.08 | 0.779 |
右肾 | 32 | 50 | ||
肿瘤最大径(cm) | 4.76±1.20 | 4.83±1.29 | 0.36 | 0.717 |
病灶纵向位置 | ||||
上下极 | 40 | 61 | 0.29 | 0.593 |
中间 | 26 | 47 | ||
病灶横向位置 | ||||
外侧 | 54 | 83 | 0.60 | 0.437 |
内侧 | 12 | 25 | ||
病灶是否外凸 | ||||
是 | 62 | 101 | 0.04 | 0.833 |
否 | 4 | 7 | ||
病灶形态学 | ||||
圆形 | 64 | 54 | ||
小叶形 | 2 | 33 | 41.41 | <0.001 |
不规则形 | 0 | 21 | ||
病理组织学类型 | ||||
肾透明细胞癌 | 53 | 87 | ||
肾乳头状细胞癌 | 8 | 11 | 0.28 | 0.871 |
肾嫌色细胞癌 | 5 | 10 | ||
术式 | ||||
开放 | 1 | 2 | <0.01 | >0.999 |
腹腔镜 | 65 | 106 | ||
手术入路 | ||||
腹腔 | 35 | 53 | 0.26 | 0.613 |
后腹腔 | 31 | 55 | ||
切缘状态 | ||||
阳性 | 0 | 1 | <0.01 | >0.999 |
阴性 | 66 | 107 | ||
手术时间(min) | 149.65±23.61 | 154.91±25.85 | 1.38 | 0.171 |
热缺血时间(min) | 16.41±2.85 | 28.80±5.51 | 16.92 | <0.001 |
术中出血量(ml) | 98.71±18.65 | 101.35±19.84 | 0.88 | 0.378 |
术后住院时间(d) | 7.50±1.29 | 7.67±1.41 | 0.81 | 0.417 |
术后24 h内肌酐升高值(μmol/L) | 12.27±1.57 | 16.79±1.95 | 16.79 | <0.001 |
术后24 h内Hb下降值(μmol/L) | 11.73±3.40 | 18.22±5.78 | 9.33 | <0.001 |
围手术期并发症 | ||||
无 | 61 | 65 | ||
Ⅰ~Ⅱ级 | 5 | 33 | 21.31 | <0.001 |
Ⅲ~Ⅳ级 | 0 | 10 | ||
R.E.N.A.L.评分(分) | 7.46±1.60 | 8.73±1.89 | 4.74 | <0.001 |
PADUA评分(分) | 8.23±2.57 | 9.58±2.88 | 3.21 | 0.002 |
C-index评分(分) | 1.67±0.36 | 1.73±0.42 | 1.00 | 0.318 |
DAP评分(分) | 7.02±1.35 | 7.17±1.38 | 0.71 | 0.482 |
梅奥肾周粘连指数 | 0.51±0.12 | 1.05±0.20 | 22.28 | <0.001 |
"
影响因素 | b值 | SE值 | Wald值 | OR值 | 95%CI | P值 |
---|---|---|---|---|---|---|
体质量指数 | -1.17 | 0.44 | 7.07 | 0.31 | 0.13~0.74 | 0.007 |
病灶形态学 | -1.02 | 0.25 | 16.65 | 0.36 | 0.22~0.59 | <0.001 |
热缺血时间 | -1.35 | 1.11 | 1.48 | 0.26 | 0.03~2.28 | 0.223 |
术后24 h内肌酐升高值 | -1.02 | 0.84 | 1.47 | 0.36 | 0.07~1.87 | 0.224 |
术后24 h内Hb下降值 | -1.66 | 0.92 | 3.26 | 0.19 | 0.03~1.15 | 0.071 |
围手术期并发症 | 1.25 | 1.02 | 1.50 | 3.49 | 0.47~25.77 | 0.220 |
R.E.N.A.L.评分 | -1.58 | 1.14 | 1.92 | 0.21 | 0.02~1.92 | 0.165 |
PADUA评分 | -0.99 | 0.40 | 6.13 | 0.37 | 0.17~0.81 | 0.013 |
梅奥肾周粘连指数 | -0.85 | 0.30 | 8.03 | 0.43 | 0.24~0.70 | 0.004 |
[1] | Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3): 209-249. DOI:10.3322/caac.21660. |
[2] | 孙争辉, 黄晓娟, 董靖晗, 等. 临床T1期肾细胞癌肾窦侵犯的危险因素[J].北京大学学报(医学版),2021,53(4): 659-664. DOI:10.19723/j.issn.1671-167X.2021.04.006. |
[3] | Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European association of urology guidelines on renal cell carcinoma: the 2019 update[J].Eur Urol,2019,75(5): 799-810. DOI:10.1016/j.eururo.2019.02.011. pmid:30803729 |
[4] | 刘鹏飞, 侯广东, 倪建鑫, 等. 保留肾单位手术后肾功能预后的影响因素分析[J].中华泌尿外科杂志,2020,41(3): 179-184. DOI:10.3760/cma.j.cn112330-20190530-00254. |
[5] | Teishima J, Hayashi T, Kitano H, et al. Impact of radiological morphology of clinical T1renal cell carcinoma on the prediction of upstaging to pathological T3[J].Jpn J Clin Oncol,2020,50(4): 473-478. DOI:10.1093/jjco/hyz154. pmid:32100866 |
[6] | Farrow JM, Kern SQ, Gryzinski GM, et al. Nephron-sparing ma-nagement of upper tract urothelial carcinoma[J].Investig Clin Urol,2021,62(4): 389-398. DOI:10.4111/icu.20210113. pmid:34190434 |
[7] | Manno S, Dell'Atti L, Cicione A, et al. Safety and efficacy of transperitoneal laparoscopic nephron sparing surgery in patients with previous abdominal surgery[J].Urologia,2021,88(1): 14-20. DOI:10.1177/0391560320921728. |
[8] | Dahlkamp L, Haeuser L, Winnekendonk G, et al. Interdisciplinary comparison of PADUA and R.E.N.A.L. scoring systems for prediction of conversion to nephrectomy in patients with renal mass scheduled for nephron sparing surgery[J].J Urol,2019,202(5): 890-898. DOI:10.1097/JU.0000000000000361. pmid:31145034 |
[9] | Sterzik A, Solyanik O, Eichelberg C, et al. Improved prediction of nephron-sparing surgery versus radical nephrectomy by the optimized R.E.N.A.L. score in patients undergoing surgery for renal masses[J].Minerva Urol Nefrol,2019,71(3): 249-257. DOI:10.23736/S0393-2249.18.03134-X. pmid:30256079 |
[10] | Li G, Zhu D, Gao H, et al. Oncologic outcomes of nephron-sparing surgery in patients with T1multifocal renal cell carcinoma[J].Clin Transl Oncol,2019,21(6): 760-765. DOI:10.1007/s12094-018-1984-3. pmid:30443869 |
[11] | 张浩洋, 孙嘉乐, 胡灿, 等. 四种肾肿瘤评分系统预测后腹腔镜下肾部分切除术临床结局的比较[J].东南大学学报(医学版),2021,40(4): 427-434. DOI:10.3969/j.issn.1671-6264.2021.04.002. |
[12] | Abu-Ghanem Y, Powles T, Capitanio U, et al. Should patients with low-risk renal cell carcinoma be followed differently after nephron-sparing surgery vs radical nephrectomy?[J].BJU Int,2021,128(3): 386-394. DOI:10.1111/bju.15415. pmid:33794055 |
[13] | Ko YH. Nephron-sparing approaches in the management of upper tract urothelial carcinoma: indications and clinical outcomes[J].Transl Cancer Res,2020,9(10): 6589-6595. DOI:10.21037/tcr.2020.03.66. pmid:35117269 |
[14] | Hakam N, Abou Heidar N, Khabsa J, et al. Does a positive surgical margin after nephron sparing surgery affect oncological outcome in renal cell carcinoma? A systematic review and meta-analysis[J].Urology,2021,156: e30-e39. DOI:10.1016/j.urology.2021.04.058. pmid:34186133 |
[15] | Kumar P, Hussain M, Jabeen M, et al. Outcomes of nephron-sparing surgery in T1vs T2renal tumours[J].J Coll Physicians Surg Pak,2022,32(5): 627-631. DOI:10.29271/jcpsp.2022.05.627. |
[16] | Borregales LD, Adibi M, Thomas AZ, et al. Predicting adherent perinephric fat using preoperative clinical and radiological factors in patients undergoing partial nephrectomy[J].Eur Urol Focus,2021,7(2): 397-403. DOI:10.1016/j.euf.2019.10.007. pmid:31685445 |
[17] | Li G, Xiao T, Wang K, et al. Histopathological validation of safe margin for nephron-sparing surgery based on individual tumor growth pattern[J].World J Surg Oncol,2021,19(1): 255. DOI:10.1186/s12957-021-02375-3. pmid:34454535 |
[18] | Hu C, Sun J, Zhang Z, et al. Parallel comparison of R.E.N.A.L., PADUA, and C-index scoring systems in predicting outcomes after partial nephrectomy: a systematic review and meta-analysis[J].Cancer Med,2021,10(15): 5062-5077. DOI:10.1002/cam4.4047. |
[19] | Egen L, Kowalewski KF, Riffel P, et al. Nephrometry scores: can preoperative assessment of sectional imaging really mirror intra-operative renal tumor anatomy?[J].Urol Int,2021,105(1-2): 108-117. DOI:10.1159/000510684. |
[20] | Zhang X, Su Z, Lv P, et al. Functional, oncological outcomes and safety of nephron-sparing surgery versus radical nephrectomy in patients with localised renal cell carcinoma with high anatomical complexity: a retrospective cohort study with propensity score matching method[J].BMJ Open,2021,11(12): e051622. DOI:10.1136/bmjopen-2021-051622. |
[21] | Hua M, Liu W, Wang C, et al. Trans-retro-peritoneal laparoscopic partial nephrectomy for posterior hilar tumor: technical feasibility and preliminary results[J].Transl Androl Urol,2023,12(11): 1638-1644. DOI:10.21037/tau-23-399. |
[22] | Haehn DA, Bajalia EM, Cockerill KJ, et al. Validation of the Mayo adhesive probability score as a predictor of adherent perinephric fat and outcomes in open partial nephrectomy[J].Transl Androl Urol,2021,10(1): 227-235. DOI:10.21037/tau-20-926. pmid:33532312 |
[23] | Yao Y, Xu Y, Gu L, et al. The Mayo adhesive probability score predicts longer dissection time during laparoscopic partial nephrectomy[J].J Endourol,2020,34(5): 594-599. DOI:10.1089/end.2019.0687. pmid:32164450 |
[24] | Attawettayanon W, Kazama A, Yasuda Y, et al. Thermal ablation versus partial nephrectomy for cT1renal mass in a solitary kidney: a matched cohort comparative analysis[J].Ann Surg Oncol,2023,10(10): 814-822. DOI:10.1245/s10434-023-14646-2. |
[1] | Li Jun, Xue Sheng, Wang Weijie, Tao Run, Zhang Jiajun.Expression of TPX2 in kidney renal clear cell carcinoma and its clinical significance[J]. Journal of International Oncology, 2023, 50(4): 214-219. |
[2] | Mei Yanxia, Zhao Yizhou. New progress of cabozantinib in the treatment of metastatic renal cell carcinoma[J]. Journal of International Oncology, 2019, 46(10): 631-633. |
[3] | Qiu Han, Kong Jun.Clinical comparative study of two kinds of modified radical mastectomy in the treatment of breast cancer patients for Ⅰ-Ⅱa stage[J]. Journal of International Oncology, 2018, 45(7): 395-399. |
[4] | Ouyang Jie, Li Hong, Chen Siyuan, Wang Libin, Li Aihui, Liu Ming, Yu Weixuan.Application of two different gastrectomy methods in proximal gastric cancer[J]. Journal of International Oncology, 2015, 42(6): 422-425. |
[5] | Huang Liangliang, Wang Delin.Markers of renal cell carcinoma stem cells[J]. Journal of International Oncology, 2014, 41(8): 668-671. |
[6] | ZHANG Ying-Meng, CHEN Long-Hua, WANG Hong-Mei.Complications in thoracic radiotherapy[J]. Journal of International Oncology, 2012, 39(8): 605-609. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||